Nuveen Asset Management LLC Decreases Stock Position in Repligen Co. (NASDAQ:RGEN)

Nuveen Asset Management LLC lowered its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 13.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 291,537 shares of the biotechnology company's stock after selling 43,567 shares during the period. Nuveen Asset Management LLC owned approximately 0.52% of Repligen worth $41,964,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Ballentine Partners LLC increased its stake in Repligen by 4.0% in the 4th quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company's stock worth $270,000 after purchasing an additional 72 shares during the period. CIBC Asset Management Inc grew its holdings in shares of Repligen by 5.0% in the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company's stock worth $246,000 after purchasing an additional 81 shares during the last quarter. Louisiana State Employees Retirement System grew its holdings in shares of Repligen by 0.7% in the fourth quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company's stock worth $2,087,000 after purchasing an additional 100 shares during the last quarter. Utah Retirement Systems grew its holdings in shares of Repligen by 1.1% in the fourth quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company's stock worth $1,338,000 after purchasing an additional 100 shares during the last quarter. Finally, Peapack Gladstone Financial Corp grew its holdings in Repligen by 5.2% in the 4th quarter. Peapack Gladstone Financial Corp now owns 2,089 shares of the biotechnology company's stock worth $301,000 after acquiring an additional 103 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Repligen Trading Down 0.2%

RGEN opened at $126.19 on Tuesday. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The stock has a market cap of $7.09 billion, a PE ratio of -247.43, a PEG ratio of 4.54 and a beta of 1.21. The business has a 50 day moving average of $132.36 and a 200-day moving average of $145.11. Repligen Co. has a 52 week low of $102.97 and a 52 week high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. During the same period last year, the company posted $0.28 EPS. Repligen's revenue was up 10.4% on a year-over-year basis. Equities research analysts predict that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on RGEN shares. Wolfe Research raised shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target on the stock in a report on Tuesday, April 29th. HC Wainwright reissued a "buy" rating and issued a $180.00 target price on shares of Repligen in a research note on Monday, May 5th. JPMorgan Chase & Co. cut their target price on Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 29th. TD Cowen started coverage on Repligen in a research note on Monday, February 10th. They set a "buy" rating and a $200.00 target price on the stock. Finally, Royal Bank of Canada decreased their target price on Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a report on Wednesday, April 30th. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $173.25.

Insider Activity

In related news, Director Margaret Pax acquired 250 shares of the stock in a transaction on Monday, March 17th. The stock was acquired at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the purchase, the director now owns 1,043 shares of the company's stock, valued at $157,169.67. This represents a 31.53% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.20% of the company's stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.